Prognostic significance of CD56 expression in patients with multiple myeloma: a meta-analysis

References

• Palumbo A, Anderson K. Multiple myeloma. New Engl J Med. 2011;364(11):1046–1060.
   PubMed Web of Science ®Google Scholar
• Smith D, Yong K. Advances in understanding prognosis in myeloma. Brit J Haematol. 2016;175(3):367–380.
   PubMed Web of Science ®Google Scholar
• Ayed A, Chang L, Moreb J. Immunotherapy for multiple myeloma: Current status and future directions. Critl Rev Oncol Hematol. 2015;96(3):399–412.
   PubMed Web of Science ®Google Scholar
• Robillard N, Wuillème S, Lodé L, et al. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target. Leukemia. 2005;19(11):2021–2022.
   PubMed Web of Science ®Google Scholar
• Ngo NT, Brodie C, Giles C, et al. The significance of tumour cell immunophenotype in myeloma and its impact on clinical outcome. J Clin Pathol. 2009;62(11):1009–1015.
   PubMed Web of Science ®Google Scholar
• Cunningham B, Hemperly J, Murray B, et al. Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science. 1987;236(4803):799–806.
   PubMed Web of Science ®Google Scholar
• Lanier L, Testi R, Bindl J, et al. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med. 1989;169(6):2233–2238.
   PubMed Web of Science ®Google Scholar
• Van Camp B, Durie B, Spier C, et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood. 1990;76(2):377–382.
   PubMed Web of Science ®Google Scholar
• Harrington A, Hari P, Kroft S. Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma. Am J Clin Pathol. 2009;132(1):60–66.
   PubMed Web of Science ®Google Scholar
• Bataille R, Jégo G, Robillard N, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy. Haematologica. 2006;91(9):1234–1240.
   PubMed Web of Science ®Google Scholar
• Damgaard T, Knudsen LM, Dahl IM, et al. Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma. Leuk Lymph. 2009;50(2):236–246.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431–438.
   PubMed Web of Science ®Google Scholar
• Tierney J, Stewart L, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• Sahara N, Takeshita A, Shigeno K, et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol. 2002;117(4):882–885.
   PubMed Web of Science ®Google Scholar
• Pan Y, Wang H, Tao Q, et al. Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma. Leuk Res. 2016;40:77–82.
   PubMed Web of Science ®Google Scholar
• Qiu Q, Zhu P, Wang MJ, et al. Expression of CD56 and CD19 in patients with newly diagnosed multiple myeloma and their relationship with karyotypes and prognosis. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24(4):1071–1078.
   PubMedGoogle Scholar
• Shi J, Sun K, Zhu ZM, et al. Prognostic significance of CD56 and CD117 expression in patients with newly diagnosed multiple myeloma treated with bortezomib-based first-line therapy. Zhonghua Xue Ye Xue Za Zhi. 2019;40(8):693–696.
   PubMedGoogle Scholar
• Skerget M, Skopec B, Zadnik V, et al. CD56 expression is an important prognostic factor in multiple myeloma even with Bortezomib induction. Acta Haematol. 2018;139(4):228–234.
   PubMed Web of Science ®Google Scholar
• Okura M, Ida N, Yamauchi T. The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era. Med Oncol. 2020;37(11):103.
   PubMed Web of Science ®Google Scholar
• Chang H, Samiee S, Yi QL. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leuk Lymphoma. 2006;47(1):43–47.
   PubMed Web of Science ®Google Scholar
• Kraj M, Sokołowska U, Kopeć-Szlezak J, et al. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leuk Lymphoma. 2008;49(2):298–305.
   PubMed Web of Science ®Google Scholar
• Hundemer M, Klein U, Hose D, et al. Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transpl. 2007;40(11):1033–1037.
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Suzuki K. Clinical and laboratory significance of CD56 (a neural cell adhesion molecule) positivity in multiple myeloma and AL amyloidosis. Int J Myelom. 2015;50(3):30–35.
   Google Scholar
• Fan QY, Wang Y, Mi JQ. Study on the efficacy of bortezomib on CD56 negative multiple myeloma patients. J Shanghai Jiaotong Univ. 2016;36(10):1445–1450.
   Google Scholar
• Iriyama N, Miura K, Hatta Y, et al. Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib. Oncol Lett. 2017;13(5):3803–3808.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhou X, Zhu JW, et al. Association of CD117 and HLA-DR expression with shorter overall survival and/or progression-free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation. Oncol Lett. 2018;16(5):5655–5666.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–2869.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010;28(30):4630–4634.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Richardson P, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007;21(1):151–157.
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C, Barillé S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12(12):1977–1982.
   PubMed Web of Science ®Google Scholar
• Koumpis E, Tassi I, Malea T, et al. CD56 expression in multiple myeloma: correlation with poor prognostic markers but no effect on outcome. Pathol Res Pract. 2021;225:1–5.
   Web of Science ®Google Scholar
• Blaheta R, Beecken W, Engl T, et al. Human cytomegalovirus infection of tumor cells downregulates NCAM (CD56): a novel mechanism for virus-induced tumor invasiveness. Neoplasia. 2004;6(4):323–331.
   PubMed Web of Science ®Google Scholar
• Ceran F, Falay M, Dağdaş S, et al. The assessment of CD56 and CD117 expressions at the time of the diagnosis in multiple myeloma patients. Turk J Haematol. 2017;34(3):226–232.
   PubMed Web of Science ®Google Scholar